This topic contains a solution. Click here to go to the answer
« previous next »

Author Question: A patient is being treated for chemotherapy-induced nausea and vomiting (CINV) with ondansetron ... (Read 77 times)

tingc95

  • Hero Member
  • *****
  • Posts: 556
on: Jul 23, 2018
A patient is being treated for chemotherapy-induced nausea and vomiting (CINV) with ondansetron (Zofran) and dexamethasone.
 
  The patient reports getting relief during and immediately after chemotherapy but has significant nausea and vomiting several days after each chemotherapy treatment. What will the nurse do?
  a. Contact the provider to discuss increasing the dose of ondansetron.
  b. Suggest giving prolonged doses of dexamethasone.
  c. Suggest adding aprepitant (Emend) to the medication regimen.
  d. Tell the patient to ask the provider about changing the ondansetron to aprepitant.

Question 2

A patient is receiving intravenous promethazine (Phenergan) 25 mg for postoperative nausea and vomiting. What is an important nursing action when giving this drug?
 
  a. Giving the dose as an IV push over 3 to 5 minutes
  b. Infusing the dose with microbore tubing and an infusion pump
  c. Observing the IV insertion site frequently for patency
  d. Telling the patient to report dry mouth and sedation


Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

bob

  • Sr. Member
  • ****
  • Posts: 343
Reply #1 on: Jul 23, 2018
Answer to Question 1

ANS: C
The current regimen of choice for patients taking highly emetogenic drugs consists of three agents: aprepitant plus dexamethasone plus a 5-HT3 antagonist, such as ondansetron. Aprepitant has a prolonged duration of action and can prevent delayed CINV as well as acute CINV. Increasing the dose of ondansetron will not help treat the delayed CINV. Glucocorticoids should be given intermittently and for short periods to avoid side effects. Changing the ondansetron to aprepitant is not recommended.

Answer to Question 2

ANS: C
If IV administration must be done with this drug, it should be given through a large-bore, freely flowing line. The site should be monitored closely for local burning or pain or any sign of extravasation, which can cause abscess formation, tissue necrosis, and gangrene requiring amputation. Giving the medication as a rapid IV push or through microbore tubing does not adequately slow the infusion or dilute the drug. Dry mouth and sedation are expected side effects of this drug and are not dangerous.


tingc95

  • Member
  • Posts: 556
Reply 2 on: Jul 23, 2018
YES! Correct, THANKS for helping me on my review

Mochi

  • Member
  • Posts: 300
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

« previous next »
 

Did you know?

About 600,000 particles of skin are shed every hour by each human. If you live to age 70 years, you have shed 105 pounds of dead skin.

Did you know?

An identified risk factor for osteoporosis is the intake of excessive amounts of vitamin A. Dietary intake of approximately double the recommended daily amount of vitamin A, by women, has been shown to reduce bone mineral density and increase the chances for hip fractures compared with women who consumed the recommended daily amount (or less) of vitamin A.

Did you know?

There are 20 feet of blood vessels in each square inch of human skin.

Did you know?

Only one in 10 cancer deaths is caused by the primary tumor. The vast majority of cancer mortality is caused by cells breaking away from the main tumor and metastasizing to other parts of the body, such as the brain, bones, or liver.

Did you know?

In the United States, an estimated 50 million unnecessary antibiotics are prescribed for viral respiratory infections.

Patient receiving ultrasound treatment to the left elbow. Patient receiving ultrasound treatment to the left elbow.
Patient learns to not be afraid Patient learns to not be afraid
All messages must be documented and placed in the patient's chart. All messages must be documented and placed in the patient's chart.
Cell kill and chemotherapy. Cell kill and chemotherapy.
A histologic slide showing the sponge-like architecture of a patient with Creutzfeldt-Jakob Disease. A histologic slide showing the sponge-like architecture of a patient with Creutzfeldt-Jakob Disease.
Video: Oral Hygiene & Braces Animation

For a complete list of videos, visit our video library